Multicenter retrospective study of initial treatment outcome and feasibility of initiating dose reduction of cabozantinib in unresectable hepatocellular carcinoma.
Tetsu TomonariJoji TaniChikara OgawaAkihiro DeguchiTomonori SenohAkio MoriyaHiroshi ShibataHiroshi FukunoHironori TanakaTakahiro TanakaTatsuya TaniguchiMasahiro SogabeYutaka KawanoAkihiro MorishitaKoichi TakaguchiHiroshi MiyamotoYasushi SatoTsutomu MasakiTetsuji TakayamaPublished in: Hepatology research : the official journal of the Japan Society of Hepatology (2022)
Our study suggests that the efficacy and safety of CAB in real-world clinical practice are comparable to those of the phase III trial (CELESTIAL), and that dose reduction of CAB may be a safer treatment option.